GTC
GPCR icon

Ghost Tree Capital’s Structure Therapeutics GPCR Stock Holding History

Ghost Tree Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-75,000
Closed -$3.21M – 73
2024
Q1 		$3.21M Sell
75,000
-75,000
-50% -$3.16M 0.89% 38
2023
Q4 		$6.11M Buy
150,000
+95,000
+173% +$5.44M 2% 13
2023
Q3 		$2.77M Buy
+55,000
New +$1.77M 0.91% 37

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ghost Tree Capital's GPCR Position: Q2 2024 in Review

Ghost Tree Capital sold out of Structure Therapeutics (GPCR) in Q2 2024, closing a stake of 75,000 shares — an estimated $3.21M sold.

Ghost Tree Capital first reported a position in GPCR in Q3 2023 and held it in 3 quarters. The position peaked at $6.11M in Q4 2023. 166 funds tracked by Wall St. Rank hold GPCR as of Q2 2024.

  • Ghost Tree Capital reported no remaining Structure Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Ghost Tree Capital sold 75,000 Structure Therapeutics shares in Q2 2024, an estimated $3.21M.
  • Ghost Tree Capital first reported a position in Structure Therapeutics in Q3 2023 and held it in 3 quarters.
  • Ghost Tree Capital's Structure Therapeutics position peaked at $6.11M in Q4 2023.
  • 166 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2024.

Based on Ghost Tree Capital's 13F filing for Q2 2024, filed 14 Aug 2024.